Can Home Health Companies Offset the CMS 6.4% Cut Through Volume Growth and Labor Efficiency?
The CMS CY2026 Home Health Final Rule imposing a 6.4% payment reduction presents a significant headwind for the home health industry. For investors in Aveanna Healthcare (AVAH) and The Ensign Group (ENSG) — the two largest publicly traded pure-play operators with meaningful home health exposure — the central question is whether operational levers can neutralize regulatory pressure. The data suggests the answer is a qualified yes, but execution risk is real.
The Regulatory Backdrop
CMS finalized a 6.4% aggregate cut to home health payment rates for calendar year 2026, driven by behavioral adjustment clawbacks tied to the Patient-Driven Groupings Model (PDGM) transition. This follows years of proposed cuts that the industry has lobbied against. Aveanna's management flagged "uncertainty around the proposed Medicare home health rule for 2026 and its potential cuts to home health benefits" as a key risk in both Q2 and Q3 2025 earnings calls, while actively engaging in advocacy efforts.
For context, Medicare home health reimbursement represents a meaningful but not dominant share of revenue for these operators. The cut applies to the Medicare fee-for-service portion, meaning the effective revenue impact is diluted across payer mixes that include Medicaid, managed care, and private pay.
Volume Growth: The Primary Offset
Aveanna Healthcare (AVAH)
Aveanna has demonstrated it can grow through reimbursement pressure. Q3 2025 revenue hit $622 million, up 22.2% year-over-year, with adjusted EBITDA of $80.1 million — a 67.5% increase. Full-year 2025 guidance was raised to revenue exceeding $2.375 billion and adjusted EBITDA above $300 million, after three consecutive quarters of upward revisions.
The volume story is compelling:
- Episodic volume growth: Home health episodic volume grew 14.2% in Q3 2025, with episodic mix reaching 77%
- Preferred payer expansion: Added 5 preferred payer agreements in Q3 alone, bringing the total to 30 — up from 22 at the start of 2025
- Thrive acquisition: The Thrive Skilled Pediatrics integration, on track for completion by end of 2025, is already accretive
Aveanna's FY2024 revenue of $2.025 billion grew 6.8% over FY2023's $1.895 billion. The acceleration into 2025 — with quarterly run rates implying $2.4 billion+ — suggests organic volume momentum that can absorb a 6.4% rate cut on the Medicare home health slice.
| Metric | FY2023 | FY2024 | Q3 2025 (annualized) |
|---|---|---|---|
| Revenue | $1.90B | $2.02B | ~$2.49B |
| EBITDA Margin | 2.1% | 9.3% | 12.9% (adj.) |
| Revenue Growth | 6.0% | 6.8% | 22.2% YoY |
The Ensign Group (ENSG)
Ensign operates primarily in skilled nursing but has been aggressively expanding its post-acute footprint. FY2025 revenue reached $5.058 billion, up 18.7% from $4.260 billion in FY2024. Management guided CY2026 to $5.77–$5.84 billion in revenue and EPS of $7.41–$7.61, representing a 14.3% earnings increase.
Ensign's volume engine is acquisition-driven:
- Added 17 new operations in Q4 2025, with 73 total since early 2024
- Same-store occupancy hit all-time highs of 83.8%, with transitioning operations at 84.9%
- Skilled days increased consistently, with Medicare and managed care revenue growing
Ensign's exposure to the home health cut is indirect — its primary business is skilled nursing facilities — but its post-acute continuum positioning means rate pressure on home health competitors could actually drive referral volume into Ensign's SNF beds.
Labor Efficiency: The Margin Lever
Labor is the largest cost for home health operators, and efficiency gains here directly offset rate reductions.
Aveanna's SG&A expenses tell a nuanced story. Q2 2025 SG&A of $122.5 million was notably lower than Q3's $143.5 million, but the company has been investing in preferred payer alignment — paying more to attract and retain caregivers while negotiating enhanced reimbursement rates from value-based payers. This is a deliberate trade-off: higher labor costs per hour, but better volume capture and payer mix.
The proof is in the margin expansion. Aveanna's EBITDA margin improved from 2.1% in FY2023 to 9.3% in FY2024, with Q2 2025 hitting 14.8% — a dramatic turnaround from the negative margins of FY2022 when the company lost $525 million in EBITDA.
Ensign's approach is different but equally effective. Operating income margins have held steady at 8.4% TTM, with EBITDA margins at 11.2%. The company's decentralized operating model — empowering local leadership teams — has produced consistent margin resilience even while absorbing dozens of underperforming acquisitions each year.
The Math: Can Growth Outrun the Cut?
A 6.4% Medicare home health rate cut, applied only to the fee-for-service Medicare portion of revenue, might translate to a 2–3% effective revenue headwind for a diversified home health operator like Aveanna. Against 15–22% top-line growth and rapidly expanding margins, the arithmetic favors the operators.
However, three risks deserve attention:
- Medicaid uncertainty: Aveanna's management warned of "general headwinds with state Medicaid systems in 2026 regarding rates." If Medicaid cuts compound with Medicare cuts, the combined pressure intensifies.
- Volume sustainability: Aveanna's 22% growth rate includes the Thrive acquisition. Organic growth alone may be closer to low double digits.
- Labor cost inflation: While preferred payer strategies improve unit economics, tight labor markets could re-compress margins if wage growth accelerates.
What to Watch
Note that Amedisys (AMED), previously the second-largest home health provider, was acquired by UnitedHealth Group's Optum division and is no longer publicly traded — narrowing the investable universe.
- AVAH Q4 2025 results: Will the 53rd week and continued preferred payer momentum sustain the margin trajectory into the CY2026 cut implementation?
- ENSG 2026 execution: Management's $7.41–$7.61 EPS guidance already incorporates the regulatory environment. Any shortfall would signal broader sector pressure.
- CMS implementation details: Final payment adjustments and any legislative relief efforts could moderate the headline 6.4% figure.
Investment Implications
The data supports a cautiously optimistic view. Both AVAH and ENSG have demonstrated volume and margin trajectories that meaningfully exceed the 6.4% headwind. Aveanna trades at 18.8x trailing earnings with 58.8% forward EPS growth expected — pricing in continued recovery. Ensign at 35x earnings with 25% forward EPS growth reflects premium-quality execution but leaves less margin for error.
The CMS cut is a headwind, not a hurricane. Companies with scale, payer diversification, and operational discipline can grow through it — but investors should monitor Medicaid developments as the more unpredictable risk factor.
Sources: Aveanna Healthcare Q2–Q3 2025 earnings calls; Ensign Group Q1–Q4 2025 earnings calls; CMS CY2026 Home Health Final Rule; company financial statements via Diggr.